-
COVER STORY
Toxicological evaluation of biosimilars
-
EDITORIAL
Biosimilar medicines
C. Lynch
-
LATEST NEWS
Fog in the Channel, continent cut off
P. Arosio
-
INTELLECTUAL PROPERTY
Biologics, biosimilars and biobetters: which IP protection?
-
MARKET ACCESS
Field-based Medical Affairs: facilitating patient access to new therapies
P. Rutherford
-
A WORD WITH
A word with… Marco Baccanti – Chief Executive of Health Industries South Australia
-
REGULATORY & COMPLIANCE
REGULATORY: Italian framework on public procedures for the purchase of biological medicinal products Biosimilarity and bioequivalence in Italian law
S. Selletti, A. Scalia
-
REGULATORY & COMPLIANCE
COMPLIANCE: The new ISO 37001 “Anti-Bribery Management Systems” has been published
G. Campalani, I. A. Savini, A. R. Carnà
-
BUSINESS NEWS
-
MERGERS & ACQUISITIONS
Notable life science mergers and acquisitions in Q3 2016
P. D’Souza
-
TECHNOLOGY
This is smashing!
M. Sandal
The potential of mechanochemistry for green pharmaceutical synthesis
-
A WORD WITH
ELISE MOUS & ANDREA CONFORTO – CAPUA BIOSERVICES
-
FOCUS ON BIOSIMILARS
Biosimilars: the challenges to bring a “new” concept to market A short review of the first decade of biosimilars
P. Cornes, M. Muenzberg
-
FOCUS ON BIOSIMILARS
Biosimilars at the interface of science, medicine and economics
U. Gudat
-
FOCUS ON BIOSIMILARS
Interchangeability and substitution: differences between biosimilars and generics
P. Rocco, P. Minghetti
-
FOCUS ON BIOSIMILARS
Biosimilars in Europe
W. A. Rehmann, D. Heimhalt
The role of EMA’s guidelines
-
PEPTIDE THERAPEUTICS
Redefining the Peptide Therapeutic Manufacturing Industry in the 21st Century (Part 2)*
E. R. Lax
Challenges for the future
-
PRODUCT & SERVICES
-
IN & OUT
-
UPCOMING EVENTS